VIATRIS (MYLAN, INC)
Sign in to add to a watchlist →
lobbying_client · US · canonical: viatris mylan · 1 alias · 5 outbound · 7 inbound
Activity
Every typed-graph event involving this entity, newest first. Each row is one edge in the influence graph; click the date to jump to its provenance.
- 2026-05-18 · lobbied by Christopher Buki · lda_lobbyist_client
- 2026-05-18 · lobbied by Shimon Stein · lda_lobbyist_client
- 2026-05-18 · lobbied by Kristi Remington · lda_lobbyist_client
- 2026-05-18 · lobbied by Ashley Davis · lda_lobbyist_client
- 2026-05-18 · lobbied by Malloy Mcdaniel · lda_lobbyist_client
- 2026-01-01 · lobbied on To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications. (h.r. 1843) · lobbying_bill_mention
- 2026-01-01 · co-acted on bill with Hassan, Margaret Wood (s1302-119) · lda_filing
- 2026-01-01 · lobbied on Preserve Access to Affordable Generics and Biosimilars Act (s.1096) · lobbying_bill_mention
- 2026-01-01 · lobbied on Affordable Prescriptions for Patients Act (s.1041) · lobbying_bill_mention
- 2026-01-01 · lobbied for by S-3 GROUP $60,000 · lda_filing
- 2026-01-01 · lobbied on Prescription Pricing for the People Act of 2025 (s.527) · lobbying_bill_mention
- 2026-01-01 · lobbied on Increasing Transparency in Generic Drug Applications Act (s.1302) · lobbying_bill_mention
Lobbying disclosures — as CLIENT (1)
Filings where this org hired a lobbying firm. Income + expenses come from the LDA disclosure.
| Posted | Filing | Year | Period | Registrant (lobbying firm) | Income | Expenses |
|---|---|---|---|---|---|---|
| 2026-04-17 | 1st Quarter - Report | 2026 | first_quarter | 400774330 | $60,000 | — |
Aliases (1)
| source | id | name at source | jurisdiction | confidence | linked by | linked at |
|---|---|---|---|---|---|---|
| lda_client | 66077 | VIATRIS (MYLAN, INC) | US | gold | backfill_0029 |
Outbound edges (5)
| date | type | to | amount | role | source |
|---|---|---|---|---|---|
| 2026-01-01 | lobbies_on_bill | HR 1843 — To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug | — | H.R. 1843 | lobbying_bill_mention |
| 2026-01-01 | lobbies_on_bill | S 1041 — Affordable Prescriptions for Patients Act | — | S.1041 | lobbying_bill_mention |
| 2026-01-01 | lobbies_on_bill | S 1096 — Preserve Access to Affordable Generics and Biosimilars Act | — | S.1096 | lobbying_bill_mention |
| 2026-01-01 | lobbies_on_bill | S 1302 — Increasing Transparency in Generic Drug Applications Act | — | S.1302 | lobbying_bill_mention |
| 2026-01-01 | lobbies_on_bill | S 527 — Prescription Pricing for the People Act of 2025 | — | S.527 | lobbying_bill_mention |
Inbound edges (7)
| date | from | type | amount | source |
|---|---|---|---|---|
| — | Kristi Remington | lobbied_for | — | lda_lobbyist_client |
| — | Malloy Mcdaniel | lobbied_for | — | lda_lobbyist_client |
| — | Ashley Davis | lobbied_for | — | lda_lobbyist_client |
| — | Shimon Stein | lobbied_for | — | lda_lobbyist_client |
| — | Christopher Buki | lobbied_for | — | lda_lobbyist_client |
| 2026-01-01 | Hassan, Margaret Wood | co_acted_on_bill_with | — | lda_filing |
| 2026-01-01 | S-3 GROUP | lobbies_for | $60,000 | lda_filing |